primat
thetadefensin
physic
distinguish
known
fullycycl
peptid
anim
origin
human
produc
thetadefensin
peptid
due
prematur
stop
codon
present
signal
sequenc
six
thetadefensin
pseudogen
instead
sinc
put
code
region
human
thetadefensin
pseudogen
remain
remark
intact
correspond
peptid
call
retrocyclin
recreat
use
solidphas
synthet
approach
retrocyclin
exhibit
except
therapeut
index
inhibitor
entri
bactericid
agent
make
retrocyclin
promis
candid
develop
topic
microbicid
prevent
sexual
transmit
diseas
review
present
evolut
antiretrovir
mechan
action
potenti
clinic
applic
retrocyclin
prevent
sexual
transmiss
wood
insight
comment
hdp
hostdefens
peptid
rc
retrocyclin
rtd
rhesu
thetadefensin
cxc
chemokin
receptor
cc
chemokin
hnp
human
neutrophil
peptid
rti
revers
transcriptas
inhibitor
defensin
one
wide
studi
famili
mammalian
hostdefens
peptid
hdp
similar
hdp
cation
charg
amphipath
natur
structur
distinguish
presenc
six
cystein
betasheet
structur
defensin
divid
alpha
beta
thetasubfamili
length
amino
acid
residu
respect
addit
nativ
antimicrobi
activ
wide
spectrum
microb
virus
defensin
also
ascrib
variou
role
host
defens
includ
abil
affect
cell
function
direct
interact
cell
membran
andor
receptor
way
defensin
modifi
immun
cell
activ
cytokin
releas
chemotaxi
antigen
present
wound
heal
angiogenesi
order
repair
epitheli
damag
prevent
spread
infect
alphaand
betadefensin
extens
review
thu
detail
herein
instead
chapter
center
thetadefensin
subfamili
defensin
particular
focu
retrocyclin
class
human
thetadefensin
potenti
prophylact
therapeut
prevent
treat
viral
microbi
infect
thetadefensin
first
discov
leukocyt
rhesu
macaqu
macrocycl
product
posttransl
headtotail
ligat
two
truncat
alphadefensin
known
circular
peptid
mammalian
origin
figur
sinc
rhesu
macaqu
express
two
differ
thetadefensin
gene
three
possibl
thetadefensin
form
homodimer
product
two
ident
copi
either
one
gene
heterodimer
product
one
copi
gene
alphaand
betadefensin
peptid
isol
character
mammal
test
date
product
thetadefensin
peptid
restrict
select
nonhuman
primat
human
thetadefensin
gene
transcrib
howev
prematur
termin
codon
signal
sequenc
preclud
translat
date
thetadefensin
peptid
report
occur
natur
human
cell
tissu
sinc
human
rhesu
macaqu
thetadefensin
gene
retain
nearli
ident
nucleotid
level
code
region
remain
intact
human
gene
human
thetadefensin
peptid
recreat
use
synthet
approach
class
thetadefensin
peptid
term
retrocyclin
retro
signifi
evolutionari
past
cyclin
denot
circular
natur
peptid
retrocyclin
thetadefensin
share
sever
attribut
typic
mani
hdp
includ
net
posit
charg
amphipath
structur
broad
spectrum
activ
gramposit
gramneg
bacteria
virus
fungi
micromolar
concentr
thetadefensin
shown
exert
bactericid
activ
gramposit
bacteria
listeria
monocytogen
staphylococcu
aureu
gramneg
bacteria
e
coli
salmonella
typhimurium
fungi
candida
albican
cryptococcu
neorforman
given
macrocycl
natur
retrocyclin
resist
digest
exopeptidas
like
contribut
increas
physiolog
stabil
biolog
fluid
tissu
section
follow
discuss
divers
peptid
resembl
structur
function
retrocyclin
evolut
retrocyclin
thetadefensin
mechan
action
retrocyclin
viral
entri
inhibitor
emphasi
futur
clinic
applic
retrocyclin
prevent
limit
transmiss
small
hairpin
peptid
amino
acid
evolutionarili
divers
speci
share
remark
structur
function
similar
retrocyclin
three
peptid
gomesin
protegrin
tachyplesinspolyphemusin
isol
spider
hemocyt
porcin
leukocyt
horsesho
crab
hemocyt
respect
gomesin
consist
amino
acid
two
intern
disulfid
bridg
result
betahairpin
structur
essenti
optim
function
studi
shown
gomesin
exhibit
activ
fungi
bacteria
protozoan
parasit
eg
p
falciparium
well
antitumor
activ
protegrin
particularli
known
potent
broadspectrum
antimicrobi
activ
target
gramposit
gramneg
bacteria
filament
fungi
yeast
cell
well
specif
virus
tachyplesin
amino
acid
peptid
ctermin
alphaamid
group
form
rigid
antiparallel
betasheet
structur
connect
betaturn
peptid
potent
activ
gramposit
gramneg
bacteria
fungi
natur
tachyplesin
exhibit
modest
antihiv
activ
tropic
virus
util
coreceptor
entri
tropic
virus
coreceptor
howev
hdp
undesir
hemolyt
activ
human
erythrocyt
show
pronounc
activ
high
salt
concentr
typic
sea
water
live
condit
horsesho
crab
manipul
backbon
via
product
cyclic
endtoend
peptid
reduc
hemolyt
activ
retain
signific
amount
antibacteri
activ
synthet
tachyplesin
eg
mimic
portion
protein
bind
rel
high
affin
quit
activ
prevent
tropic
infect
lymphocyt
comparison
structur
function
similar
retrocyclin
vertebr
invertebr
hdp
provid
figur
tabl
small
subset
hdp
cyclic
natur
divers
group
cyclic
peptid
cyclotid
produc
plant
cyclotid
first
identifi
isol
violacea
violet
rubiacea
coffe
cucurbitacea
cucurbit
famili
may
present
plant
speci
well
cyclotid
small
amino
acid
protein
three
interlock
disulfid
bond
result
cystin
knot
motif
contribut
significantli
protein
stabil
characterist
distinguish
mani
protein
peptid
stabl
high
temperatur
resist
proteas
chemic
chaotrop
cyclotid
wide
rang
inher
biolog
activ
includ
follow
uteroton
antihiv
neurotensin
antagon
hemolysi
antimicrobi
cytotox
insecticid
antihelmint
activ
due
signific
stabil
uniqu
cyclotid
synthes
number
amino
acid
sequenc
replac
give
capac
either
modifi
optim
inher
activ
use
scaffold
biolog
activ
epitop
similar
synthet
approach
use
creat
congen
retrocyclin
enhanc
antivir
antimicrobi
activ
select
attribut
desir
toward
develop
retrocyclin
therapeut
prevent
sever
studi
reveal
defensin
defici
could
potenti
patholog
signific
variou
diseas
condit
includ
crohn
diseas
atop
dermat
bacteri
vaginosi
specul
best
suscept
hiv
progress
aid
may
part
due
genet
defici
retrocyclin
express
occur
human
significantli
test
strain
highli
suscept
inhibit
retrocyclin
siv
less
suscept
unpublish
observ
specul
dichotomi
two
hiv
serotyp
may
result
evolut
evolv
siv
whose
natur
host
old
world
monkey
still
express
thetadefensin
major
evolv
sivcpz
whose
natur
host
chimpanze
primat
express
thetadefensin
consequ
may
evolv
select
pressur
thetadefensin
case
virus
may
suscept
presenc
reawaken
retrocyclin
analysi
role
retrocyclin
protect
infect
spread
discuss
natur
synthes
retrocyclin
peptid
detect
human
cell
tissu
howev
retrocyclinencod
mrna
transcript
present
bone
marrow
cell
spleen
thymu
test
skelet
muscl
retrocyclin
peptid
detect
prematur
termin
codon
present
signalpeptid
sequenc
prevent
translat
figur
analysi
evolut
prematur
termin
codon
five
prosimian
six
new
world
monkey
five
old
world
monkey
one
lesser
ape
four
great
ape
reveal
prematur
termin
codon
present
human
along
closest
primat
rel
chimpanze
gorilla
new
world
monkey
prosimian
old
world
monkey
eg
rhesu
macaqu
thetadefensin
origin
isol
review
importantli
orangutan
human
evolv
million
year
ago
intact
silenc
copi
thetadefensin
gene
suggest
prematur
termin
codon
mutat
occur
approxim
fork
evolut
interestingli
human
cell
make
retrocyclin
peptid
natur
certain
cell
retain
abil
produc
peptid
coax
compound
suppress
prematur
termin
codon
although
may
never
fulli
comprehend
evolutionari
import
introduct
prematur
termin
codon
determin
function
retrocyclin
may
help
answer
import
genet
question
termin
codon
came
remain
conserv
five
six
human
thetadefensin
gene
cluster
chromosom
genom
region
high
divers
mani
defensin
gene
locat
sole
except
thetadefensinencod
gene
chromosom
due
similar
sequenc
retrocyclin
gene
appear
deriv
truncat
alphadefensin
gene
figur
inde
alphadefensin
close
relat
thetadefensin
particular
note
asid
prematur
nonsens
mutat
six
retrocyclin
gene
remark
intact
given
retrocyclin
gene
locat
region
chromosom
known
high
genet
divers
puzzl
retrocyclin
gene
remain
intact
million
year
sever
possibl
retrocyclin
gene
might
lucki
enough
escap
mutat
supposit
introduct
prematur
nonsens
mutat
occur
hominid
evolut
might
incorrect
perhap
like
explan
retrocyclin
retain
contemporari
function
heretofor
unknown
support
studi
reveal
human
cell
retain
complex
machineri
necessari
process
retrocyclin
peptid
right
condit
prematur
termin
codon
may
fact
yield
rather
true
stop
translat
similar
rtd
rhesu
monkey
human
also
two
differ
retrocyclin
gene
could
theoret
combin
creat
three
differ
cyclic
peptid
two
homodim
heterodim
three
differ
human
retrocyclin
solidphas
synthes
test
antivir
activ
sever
cellbas
assay
measur
viral
releas
lymphocyt
cell
line
pbmc
interest
net
posit
charg
net
posit
charg
activ
strain
test
net
posit
charg
activ
prove
activ
three
primari
isol
thu
use
studi
retrocyclin
structur
moreov
synthet
retrocyclin
analog
term
engin
net
posit
charg
likewis
inact
togeth
find
suggest
similar
mode
action
mani
hdp
bacteria
fungi
electrostat
interact
might
import
abil
retrocyclin
prevent
infect
similar
defensin
envelop
glycoprotein
hiv
deserv
discuss
observ
nearli
two
decad
prior
defensin
inhibit
replic
vitro
structur
resembl
portion
fusogen
protein
moreov
peptid
defensin
form
trimer
antiparallel
helic
loop
insert
membran
thu
defensin
may
exert
antivir
activ
part
competit
inhibitor
membran
bind
fusion
process
initi
entri
solut
form
trimer
structur
concentrationdepend
manner
figur
lower
concentr
particular
structur
form
betapl
sheet
howev
higher
concentr
trimer
structur
form
bind
membran
prolat
structur
monom
stabil
allow
format
stabl
trimer
comparison
rhesu
macaqu
thetadefensin
potent
higher
bind
affin
human
possess
rigid
structur
selfassoci
lower
concentr
trimer
retrocyclin
structur
like
increas
dramat
affin
retrocyclin
glycoprotein
whether
structur
similar
retrocyclin
defensin
coincident
result
viral
molecular
mimicri
remain
unclear
futur
studi
examin
relationship
might
reveal
portion
mimic
certain
defensinlik
action
host
immun
section
examin
molecular
characterist
retrocyclin
bind
includ
bind
affin
mutant
correl
activ
bind
host
receptor
residu
length
appar
lack
complex
made
retrocyclin
particularli
attract
mutagenesi
studi
design
identifi
retrocyclin
congen
greater
biolog
activ
favor
drug
metabol
ultim
greater
clinic
potenti
effort
investig
antivir
role
residu
develop
rc
congen
superior
potenc
tyrosin
scan
noncystein
residu
perform
entireti
superior
tyrosinecontain
congen
obtain
replac
one
four
arginin
residu
abrog
activ
howev
chargeconserv
substitut
one
arginin
lysin
result
congen
increas
potenc
ultim
indic
certain
modif
retrocyclin
sequenc
potenti
greater
potenc
parent
molecul
low
micromolar
ic
activ
prevent
infect
host
cell
sequenc
present
figur
retrocyclin
bind
high
affin
glycoprotein
host
cell
glycoprotein
due
part
lectinlik
properti
retrocyclin
tabl
lectin
repres
vital
extracellular
carbohydratebind
protein
involv
infecti
diseas
develop
immunolog
function
compos
amino
acid
retrocyclin
one
smallest
known
lectin
notabl
first
describ
lectin
bind
envelop
glycoprotein
glycosyl
protein
includ
galactosylceramid
shown
potenti
act
addit
cell
surfac
receptor
cell
lack
bind
much
greater
affin
bind
galactosylceramid
ident
affin
importantli
retrocyclin
potent
antivir
activ
observ
sever
virus
asid
case
retrocyclin
disrupt
bind
viral
glycoprotein
host
cell
glycoprotein
remov
viral
glycosyl
group
prevent
retrocyclin
bind
retrocyclin
bind
host
cell
glycoprotein
prevent
viru
bind
target
host
cell
fact
major
mechan
retrocyclin
involv
inactiv
nonlectin
fashion
suggest
retrocyclin
abil
bind
viral
host
glycoprotein
like
place
right
place
right
time
exert
subsequ
activ
entri
target
cell
involv
sequenti
multistep
process
includ
viral
attach
host
receptor
bind
host
coreceptor
fusion
viral
host
cell
membran
hiv
glycoprotein
compris
heterotrim
consist
three
surfac
subunit
three
transmembran
subunit
trimer
bind
trimer
host
receptor
present
macrophag
lymphocyt
dendrit
cell
conform
chang
occur
enabl
bind
either
coreceptor
depend
tropism
viru
tropic
strain
util
tropic
strain
util
bind
receptor
coreceptor
outer
domain
transmembran
protein
undergo
signific
conform
chang
form
membranepenetr
fusogen
coiledcoil
trimer
consist
six
helic
three
antiparallel
leucineisoleucin
zipper
requir
membran
fusion
host
cell
step
retrocyclin
interfer
prevent
viral
entri
block
helix
bundl
format
addit
retrocyclin
bind
high
affin
k
like
aid
process
interact
retrocyclin
occur
two
heptad
repeat
domain
silico
vitro
experiment
data
indic
prefer
bind
domain
via
ionic
interact
posit
charg
cation
retrocyclin
neg
charg
domain
mutat
greater
effect
retrocyclin
bind
activ
mutat
alphadefensin
inhibit
infect
greatest
potenc
although
bind
bind
given
retrocyclin
similar
collect
observ
suggest
retrocyclin
bind
might
signific
antivir
activ
bind
lectin
characterist
retrocyclin
also
play
requir
role
antivir
activ
protein
nglycosyl
site
carbohydr
account
approxim
weight
given
retrocyclin
bind
depend
presenc
glycosyl
group
potenti
differ
seen
bind
differ
strain
may
due
differ
glycosyl
pattern
variant
remov
either
olink
nlink
sugar
immobil
glycosyl
result
consider
reduct
rc
bind
activ
remov
type
sugar
nearli
abolish
rc
bind
activ
retrocyclin
like
hdp
cation
bind
neg
charg
residu
expos
bacteria
cation
hdp
stimul
bacteria
evolv
resist
select
strain
undergon
genet
mutat
phospholipidlipopolysaccharid
synthesi
alter
neg
membran
charg
similarli
bacteria
evolv
respons
select
pressur
alter
surfac
charg
viral
envelop
glycoprotein
new
strain
viru
commonli
evolv
resist
drug
within
week
exposur
review
refer
thu
therapeut
includ
nextgener
retrocyclin
must
capabl
persist
inhibit
target
critic
amino
acid
residu
requir
infect
toward
goal
understand
potenti
resist
retrocyclin
survey
env
sequenc
hundr
primari
isol
obtain
lo
alamo
databas
suggest
strain
would
like
suscept
inhibit
treatment
retrocyclin
subsequ
sitedirect
analys
ten
repres
cationicmut
isol
reveal
one
mutant
becam
partial
resist
examin
potenti
mechan
resist
hivinfect
human
lymphocyt
cell
serial
passag
presenc
day
fiveday
round
infect
even
infect
cell
cultur
presenc
concentr
lower
toler
human
cell
inhibit
infect
least
addit
nine
round
infect
compar
data
hiv
entri
inhibitor
increas
hivresist
similar
passag
experi
induc
minim
resist
surprisingli
data
suggest
mutat
prevent
bind
protein
also
reduc
infect
thu
impart
viral
fit
consequ
subvert
retrocyclin
action
ultim
even
passag
beyond
day
result
evolut
singl
fulli
resist
strain
amc
unpublish
result
physiolog
studi
also
demonstr
activ
incub
period
cervicovagin
tissu
even
mix
vagin
fluid
import
factor
test
therapeut
vagin
deliveri
sinc
low
ph
proteolyt
action
within
vagin
mucosa
could
potenti
inhibit
activ
variou
compound
furthermor
induc
inflamm
histotox
concentr
mani
fold
higher
requir
antivir
activ
organotyp
tissu
recent
formul
quickdissolv
film
safe
remain
antivir
activ
follow
repeat
topic
vagin
applic
pigtail
macaqu
collect
observ
indic
highli
effect
mani
evolv
strain
potenti
succeed
clinic
set
sexual
transmiss
primari
mode
infect
million
peopl
infect
worldwid
women
account
half
estim
new
infect
occur
year
sinc
unprotect
heterosexu
vagin
intercours
becom
main
rout
infect
therapeut
strategi
enabl
women
control
exposur
sexual
transmit
infect
sti
critic
therapi
focus
vagin
deliveri
consid
greatest
valu
localact
drug
prevent
spread
sti
hiv
known
cross
vagin
mucosa
unknown
mechan
may
directli
involv
vagin
epitheli
cell
viru
enter
lamina
propria
directli
infect
cell
macrophag
possibl
dendrit
cell
traffic
lymph
node
becom
factori
viru
product
due
natur
broad
antimicrobi
activ
develop
retrocyclin
therapeut
agent
prevent
sti
hiv
distinct
advantag
retrocyclin
would
like
immedi
presenc
target
mucos
site
eg
vagina
cervix
lack
cytotox
inflammatori
potenti
bioactiv
concentr
exhibit
strong
activ
broad
rang
strain
hiv
topic
vagin
microbicid
may
prevent
hiv
transmiss
destroy
inhibit
viru
augment
natur
immun
defens
viru
block
viral
attach
entri
prevent
transmigr
viru
mucosa
region
lymph
node
moreov
vagin
therapi
consid
localact
therapi
rather
vast
network
blood
suppli
larg
surfac
area
vagina
provid
signific
potenti
system
drug
deliveri
avoid
problem
firstpass
metabol
encount
oral
therapi
import
note
vagin
structur
composit
also
neg
affect
drug
deliveri
sinc
one
common
enzym
found
vagin
fluid
belong
aminopeptidas
famili
exhibit
strong
protein
peptid
degrad
activ
furthermor
enzymat
activ
present
vagin
fluid
yet
complet
elucid
role
vagin
mucosa
health
diseas
still
uncov
detail
discuss
vagin
physiolog
potenti
effect
deliveri
efficaci
drug
treatment
discuss
elsewher
microbicid
candid
current
preclin
clinic
trial
target
viru
via
differ
mechan
action
includ
virucid
entryfus
inhibitor
reversetranscriptas
inhibitor
integras
inhibitor
proteas
inhibitor
current
dozen
plannedfund
trial
studi
microbicid
preexposur
prophylaxi
result
least
eight
ongo
efficaci
trial
use
microbicid
treatment
prevent
aid
sti
report
next
two
year
summari
trial
present
shown
tabl
date
success
studi
topic
vagin
microbicid
recent
centr
aid
programm
research
south
africa
caprisa
phase
trial
primari
object
studi
assess
safeti
efficaci
tenofovir
nucleotid
analogu
revers
transcriptas
inhibitor
nrti
vagin
microbicid
gel
prevent
hiv
infect
approxim
south
african
women
age
secondari
endpoint
includ
assess
tenofovir
resist
hiv
seroconvert
viral
load
women
may
becom
infect
trial
evid
deep
epitheli
disrupt
renal
toxic
impact
pregnanc
rate
outcom
reduct
infect
observ
tenofovir
gel
treatment
greatest
reduct
observ
women
high
adher
rate
appli
gel
despit
continu
use
tenofovir
gel
peak
protect
seen
month
steadili
reduc
effect
month
reason
reduc
effect
unknown
time
may
due
number
factor
includ
reduc
adher
initi
review
indic
tenofovirrel
hiv
resist
studi
need
includ
earlier
time
point
well
test
genit
system
tract
increas
impact
renal
hepat
pregnancyrel
genitalrel
advers
event
also
renal
toxicityhepat
flare
observ
may
due
low
system
absorpt
gel
formul
togeth
promis
result
set
stage
nextgener
topic
microbicid
latestag
preclin
studi
enter
earli
clinic
trial
voic
phase
trial
also
explor
use
tenofovir
gel
well
tenofovir
tablet
either
alon
combin
emtricitabin
nrti
estim
effect
prevent
hiv
acquisit
women
africa
wwwavacorghta
secondari
object
includ
rise
drug
resist
trial
subject
evalu
adher
accept
drug
dosag
form
gel
vs
tablet
studi
similar
caprisa
studi
describ
voic
focus
daili
dose
caprisa
focus
coitallyrel
dose
februari
preliminari
result
report
phase
hptn
trial
studi
effect
pro
gel
polyanion
naphthalen
sulfon
polym
bind
nanomolar
affin
prevent
bind
buffergel
carbopol
polyacryl
acid
buffer
gel
enhanc
natur
protect
action
vagina
produc
broadspectrum
microbicid
environ
placebo
extens
phase
placebocontrol
studi
mdp
pro
women
six
center
africa
fail
show
differ
effect
pro
compar
placebo
despit
report
earlier
smaller
phase
studi
indic
borderlin
effect
pro
mdp
trial
result
http
wwwafricacentreaczadefaultaspx
dapivirin
microbicid
nonnucleosid
rti
inhibit
revers
transcript
bind
conserv
region
transcriptas
prevent
progress
dapivirin
clinic
test
efficaci
gel
deliv
vagin
ring
studi
ipm
complet
phase
studi
indic
twice
daili
administr
gel
day
safe
welltoler
wwwavacorghta
addit
trial
plan
includ
phase
efficaci
trial
start
well
trial
compar
differ
formul
tablet
softcel
capsul
film
placebo
phase
trial
femprep
underway
evalu
safeti
efficaci
prevent
hiv
infect
hivneg
women
kenya
malawi
tanzania
south
africa
zambia
risk
becom
infect
sexual
intercours
truvada
fix
dose
emtricitabin
mg
tenofovir
disoproxil
fumar
mg
primari
outcom
measur
determin
combin
incid
infect
well
liver
toxic
frequenc
advers
event
associ
drug
administr
dendrim
class
polyanion
macromolecul
develop
vagin
microbicid
prevent
viruscel
interact
thu
inhibit
infect
result
first
clinic
studi
report
studi
safeti
pharmacokinet
healthi
women
gel
shown
safe
welltoler
seven
consecut
daili
dose
escal
dose
level
cervicovagin
fluid
sampl
taken
studi
particip
hour
dose
sampl
test
laboratori
abil
prevent
hiv
genit
herp
infect
suscept
cell
timepoint
postdos
fluid
sampl
abl
prevent
vitro
infect
hivsuscept
cell
efficaci
trial
need
determin
clinic
efficaci
studi
particip
confirm
vitro
data
acidform
gel
develop
provid
longlast
coat
vagin
cervic
area
order
maintain
spermicid
potenti
microbicid
vagin
ph
initi
phase
feasibl
studi
diaphragm
coat
acidform
gel
indic
women
will
abl
use
devic
six
month
benefit
protect
hiv
infect
determin
futur
trial
current
phase
trial
report
invis
phase
trial
plan
microbicid
nonnucleotid
rti
administ
gel
invis
condom
gel
formul
contain
sodium
lauryl
sulfat
polym
trap
hinder
virus
prevent
attach
subsequ
entri
suscept
cell
vitro
sodium
lauryl
sulfat
shown
prevent
hiv
attach
cell
inhibit
cell
entri
hsv
nonnucleosid
rti
demonstr
antihiv
activ
vitro
antirtshiv
bear
hiv
revers
transcriptas
vivo
macaqu
sinc
antiretrovir
product
develop
use
primarili
develop
countri
societ
cultur
issu
address
greatli
impact
drug
use
efficaci
use
condom
coitallyrel
product
addit
mani
gel
formul
often
found
studi
particip
leaki
messi
greatli
affect
protocol
adher
howev
formul
found
accept
case
found
enhanc
experi
eg
buffergel
pro
trial
data
although
firstgener
microbicid
current
phase
clinic
develop
gel
formul
newer
product
develop
explor
dosag
form
film
foam
oral
tablet
vagin
suppositori
intravagin
ring
addit
gel
product
may
coitallyindepend
may
system
activ
sever
week
possibl
month
dosag
multiregimen
therapi
also
explor
allow
prevent
one
drug
prevent
sti
concept
second
drugtherapi
retrocyclin
identifi
potenti
new
class
small
molecul
could
inhibit
entri
fusion
significantli
synthet
peptid
littl
hemolyt
activ
cytotox
common
experiment
cell
line
tcell
cervic
carcinoma
cell
concentr
highest
amount
test
studi
far
greater
concentr
rang
shown
provid
protect
strain
serial
passag
hivinfect
cell
presenc
concentr
lower
toler
limit
human
cell
result
inhibit
viral
infect
multipl
passag
significantli
mutant
replic
respons
select
pressur
reduc
infect
furthermor
retrocyclin
shown
effect
protect
primari
cell
strain
vitro
protect
primari
cell
infect
clinic
isol
multipl
clade
prevent
organotyp
cervicovagin
tissu
infect
importantli
lack
inflamm
abil
retain
potent
antihiv
activ
presenc
vagin
fluid
tissu
factor
critic
clinic
develop
retrocyclin
microbicid
prevent
transmiss
studi
continu
look
class
hdp
observ
amino
acid
substitut
could
introduc
retrocyclin
backbon
maintain
structur
integr
improv
target
activ
microbicid
clinic
trial
result
obtain
far
includ
rti
polyanion
compound
howev
microbicid
function
fusionentri
inhibitor
current
consid
greatest
clinic
potenti
shown
consist
vigor
protect
vagin
hiv
transmiss
macaqu
addit
class
microbicid
also
tend
present
greater
effect
drugresist
virus
microbicid
target
point
viral
replic
cycl
revers
transcript
success
overal
protect
hiv
infect
andor
spread
may
best
achiev
combin
effect
hdp
inhibitor
exhibit
differ
mechan
action
use
microbicid
might
greatest
effect
initi
stage
infect
could
reduc
initi
viremia
reduct
could
subsequ
lead
smaller
manag
initi
impact
immun
system
shift
balanc
toward
immun
control
although
hdp
target
microb
virus
exist
togeth
evolut
hdp
includ
retrocyclin
remain
highli
effect
target
may
best
approach
safe
effect
microbicid
near
futur
retrocyclin
origin
isol
search
small
molecul
resembl
isol
porcin
leukocyt
possess
except
antibacteri
activ
similar
small
hdp
includ
tachyplesin
gomesin
found
arthropod
tarantula
spider
horsesho
crab
respect
